Display options
Cite
Vazin A, Davarpanah MA, Ghalesoltani S. Antifungal agent utilization evaluation in hospitalized neutropenic cancer patients at a large teaching hospital. Drug Healthc Patient Saf. 2015;7:97-102doi: 10.2147/DHPS.S80762.
Vazin, A., Davarpanah, M. A., & Ghalesoltani, S. (2015). Antifungal agent utilization evaluation in hospitalized neutropenic cancer patients at a large teaching hospital. Drug, healthcare and patient safety, 797-102. https://doi.org/10.2147/DHPS.S80762
Vazin, Afsaneh, et al. "Antifungal agent utilization evaluation in hospitalized neutropenic cancer patients at a large teaching hospital." Drug, healthcare and patient safety vol. 7 (2015): 97-102. doi: https://doi.org/10.2147/DHPS.S80762
Vazin A, Davarpanah MA, Ghalesoltani S. Antifungal agent utilization evaluation in hospitalized neutropenic cancer patients at a large teaching hospital. Drug Healthc Patient Saf. 2015 Jun 01;7:97-102. doi: 10.2147/DHPS.S80762. eCollection 2015. PMID: 26064070; PMCID: PMC4457220.
Copy Download .nbib Format: NLM
Share it on

Drug Healthc Patient Saf. 2015 Jun 01;7:97-102. doi: 10.2147/DHPS.S80762. eCollection 2015.

Antifungal agent utilization evaluation in hospitalized neutropenic cancer patients at a large teaching hospital.

Drug, healthcare and patient safety

Afsaneh Vazin, Mohammad Ali Davarpanah, Setareh Ghalesoltani

Affiliations

  1. Department of Clinical Pharmacy, Faculty of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.
  2. HIV Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
  3. International Branch of Faculty of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.

PMID: 26064070 PMCID: PMC4457220 DOI: 10.2147/DHPS.S80762

Abstract

To evaluate pattern of using of three antifungal drugs: fluconazole, amphotericin B and voriconazole, at the hematology-oncology and bone marrow transplant wards of one large teaching hospital. In a prospective cross-sectional study, we evaluated the appropriateness of using antifungal drugs in patients, using Infectious Disease Society of America (IDSA) and National Comprehensive Cancer Network (NCCN) guidelines. All the data were recorded daily by a pharmacist in a form designed by a clinical pharmacist and infectious diseases specialist, for antifungals usage, administration, and monitoring. During the study, 116 patients were enrolled. Indications of prescribing amphotericin B, fluconazole, and voriconazole were appropriate according to guidelines in 83.4%, 80.6%, and 76.9% respectively. The duration of treatments were appropriate according to guidelines in 75%, 64.5%, and 71.1% respectively. The dose of voriconazole was appropriate according to guidelines in 46.2% of patients. None of the patients received salt loading before administration of amphotericin B. The most considerable problems with the mentioned antifungals were about the indications and duration of treatment. In addition, prehydration for amphotericin B and dosage of voriconazole were not completely compatible with the mentioned guidelines. A suitable combination of controlling the use of antifungals and educational programs could be essential for improving the general process of using antifungal drugs at our hospital.

Keywords: amphotericin B; fluconazole; neutropenia; utilization evaluation; voriconazole

References

  1. J Antimicrob Chemother. 2002 Feb;49 Suppl 1:81-6 - PubMed
  2. Clin Infect Dis. 2011 Feb 15;52(4):e56-93 - PubMed
  3. Kidney Int. 2001 Oct;60(4):1452-9 - PubMed
  4. J Am Soc Nephrol. 2004 Jun;15(6):1597-605 - PubMed
  5. J Am Soc Nephrol. 2005 Nov;16(11):3365-70 - PubMed
  6. J Chemother. 2000 Dec;12(6):463-70 - PubMed
  7. Clin Infect Dis. 2002 Dec 15;35(12):e120-7 - PubMed
  8. N Engl J Med. 2002 Jan 24;346(4):225-34 - PubMed
  9. Lancet Infect Dis. 2005 Oct;5(10):609-22 - PubMed
  10. J Antimicrob Chemother. 2013 Jul;68(7):1669-78 - PubMed
  11. J Antimicrob Chemother. 2008 Jul;62(1):142-8 - PubMed
  12. Bone Marrow Transplant. 2004 May;33(9):943-8 - PubMed
  13. Drugs. 2011 Dec 24;71(18):2405-19 - PubMed
  14. Arch Intern Med. 1987 Mar;147(3):593-5 - PubMed
  15. J Am Acad Dermatol. 2010 Jan;62(1):31-7 - PubMed
  16. Clin Infect Dis. 1995 Apr;20(4):755-61 - PubMed
  17. Antibiot Khimioter. 2004;49(8-9):52-6 - PubMed
  18. Clin Infect Dis. 1999 Feb;28(2):331-40 - PubMed
  19. N Engl J Med. 2007 Jan 25;356(4):348-59 - PubMed
  20. Br J Haematol. 2000 Aug;110(2):273-84 - PubMed
  21. Haematologica. 2012 Mar;97(3):459-63 - PubMed
  22. Iran J Pharm Res. 2012 Winter;11(1):151-6 - PubMed

Publication Types